Shares of Gamida Cell Ltd. (GMDA) are soaring over 60% in pre-market today, after the company announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.
from RTT - Before the Bell https://ift.tt/2AnkJd5
via IFTTT
No comments:
Post a Comment